BioWorld7d
Vertex wins FDA nod for Journavx, new mechanism for acute pain
An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...
Nasdaq25d
Eisai and Biogen Announce FDA Acceptance of Lecanemab Subcutaneous Autoinjector Application for Alzheimer's Disease Treatment
The announcement highlights LEQEMBI's dual mechanism in combating Alzheimer's by clearing both protofibrils and amyloid plaques, and continues to emphasize the anticipated ease of administration ...
Zacks.com on MSN11d
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
The FDA's approval is based on simulation data from multiple studies showing that maintenance dosing with Biogen???s Leqembi ...
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...
Medindia13d
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LEQEMBI is indicated for the treatment of ... can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aß plaques but also increasing ...
Hosted on MSN4d
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the ...